Evidence map›Paper›PMID 35902888›Full record

ArticleAddiction science & clinical practice2022

The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use disorder.

Allison J Ober, Cristina Murray-Krezan, Kimberly Page, Peter D Friedmann, Karen Chan Osilla, Stephen Ryzewicz, Sergio Huerta, Mia W Mazer, Isabel Leamon, Gabrielle Messineo and 3 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in Addiction science & clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05086796 (Substance Use Treatment and Recovery Team), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05086796 nacompletednot on this map

Substance Use Treatment and Recovery Team

TypeinterventionalSponsorCedars-Sinai Medical CenterRan2021 to 2023Enrolled325ConditionsOpioid-use Disorder, Opioid-Related DisordersArmsSubstance Use Treatment and Recovery Team (START)
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Allison J OberRAND Corporation, 1776 Main St, Santa Monica, CA, 90407-2138, USA. ober@rand.org.ORCID 0000-0001-9333-0225
Cristina Murray-KrezanUniversity Pittsburgh, Pittsburgh, PA, USA.
Kimberly PageUniversity of New Mexico Hospital, Albuquerque, NM, USA.
Peter D FriedmannUniversity of Massachusetts Chan Medical School-Baystate, Springfield, MA, USA.
Karen Chan OsillaStanford University, Palo Alto, CA, USA.
Stephen RyzewiczUniversity of Massachusetts Chan Medical School-Baystate, Springfield, MA, USA.
Sergio HuertaUniversity Pittsburgh, Pittsburgh, PA, USA.
Mia W MazerCedars Sinai Medical Center, Los Angeles, CA, USA.
Isabel LeamonRAND Corporation, 1776 Main St, Santa Monica, CA, 90407-2138, USA.
Gabrielle MessineoCedars Sinai Medical Center, Los Angeles, CA, USA.
Katherine E WatkinsRAND Corporation, 1776 Main St, Santa Monica, CA, 90407-2138, USA.
Teryl NuckolsCedars Sinai Medical Center, Los Angeles, CA, USA.
Itai DanovitchCedars Sinai Medical Center, Los Angeles, CA, USA.

Funding

UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
Collaborative care teams for hospitalized patients with opioid use disorders: Translating evidence into practiceU01TR002756 · NCATS · CEDARS-SINAI MEDICAL CENTER · PI DANOVITCH, ITAI, OBER, ALLISON · 2020 to 2023
$5.0M
NCATS NIH HHS U01 TR002756NCATS NIH HHS UL1 TR001449
6 · The paper itself

Abstract

backgroundPeople with opioid use disorder experience high burden of disease from medical comorbidities and are increasingly hospitalized with medical complications. Medications for opioid use disorder are an effective, life-saving treatment, but patients with an opioid use disorder admitted to the hospital seldom initiate medication for their disorder while in the hospital, nor are they linked with outpatient treatment after discharge. The inpatient stay, when patients may be more receptive to improving their health and reducing substance use, offers an opportunity to discuss opioid use disorder and facilitate medication initiation and linkage to treatment after discharge. An addiction-focus consultative team that uses evidence-based tools and resources could address barriers, such as the need for the primary medical team to focus on the primary health problem and lack of time and expertise, that prevent primary medical teams from addressing substance use.

methodsThis study is a pragmatic randomized controlled trial that will evaluate whether a consultative team, called the Substance Use Treatment and Recovery Team (START), increases initiation of any US Food and Drug Administration approved medication for opioid use disorder (buprenorphine, methadone, naltrexone) during the hospital stay and increases linkage to treatment after discharge compared to patients receiving usual care. The study is being conducted at three geographically distinct academic hospitals. Patients are randomly assigned within each hospital to receive the START intervention or usual care. Primary study outcomes are initiation of medication for opioid use disorder in the hospital and linkage to medication or other opioid use disorder treatment after discharge. Outcomes are assessed through participant interviews at baseline and 1 month after discharge and data from hospital and outpatient medical records. DISCUSSION: The START intervention offers a compelling model to improve care for hospitalized patients with opioid use disorder. The study could also advance translational science by identifying an effective and generalizable approach to treating not only opioid use disorder, but also other substance use disorders and behavioral health conditions.

trial registrationClinicaltrials.gov: NCT05086796, Registered on 10/21/2021. https://www. CLINICALTRIALS: gov/ct2/results?recrs=ab&cond=&term=NCT05086796&cntry=&state=&city=&dist  = .

Indexed as

BuprenorphineOpioid-Related DisordersAftercareHumansMethadoneOpiate Substitution TreatmentPatient DischargePragmatic Clinical Trials as TopicRandomized Controlled Trials as TopicBuprenorphineMethadoneAddiction consult teamCollaborative careInpatientLinkage to follow-upMedications for opioid use disorder (MOUD)Opioid use disorder (OUD)

Identifiers

PMID35902888
PMCPMC9331017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.